Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.45 |
| ▸ | LOX | P28300 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4172840 | 0.99 | LOXL2 (0.44) | LOXL2LOXHRH3ACHEHRH4 | |
| SCHEMBL27703765 | 0.84 | HRH3 (0.42) | HRH3ACHEHRH4KDM4EMEN1 | |
| SCHEMBL4098507 | 0.82 | LOXL2 (0.53) | LOXL2LOXHRH3HRH4KMT2A | |
| SCHEMBL31421129 | 0.82 | LOXL2 (0.53) | LOXL2LOXHRH3HRH4KMT2A | |
| SCHEMBL17379520 | 0.82 | LOXL2 (0.53) | LOXL2LOXHRH3HRH4KMT2A | |
| SCHEMBL31421498 | 0.82 | LOXL2 (0.53) | LOXL2LOXHRH3HRH4KMT2A | |
| SCHEMBL27685196 | 0.82 | HRH3 (0.40) | HRH3ACHEHRH4KDM4EMEN1 | |
| SCHEMBL4168208 | 0.81 | HRH3 (0.47) | HRH3HRH4HRH1 | |
| SCHEMBL21492519 | 0.81 | LOXL2 (0.51) | LOXL2LOXHRH4LOXL3 | |
| SCHEMBL30744375 | 0.81 | LOXL2 (0.51) | LOXL2LOXHRH4LOXL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612076-B2 | Piperazinyl-pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | claimed |
| US-20090042903-A1 | PIPERAZINYL-PYRIDINE DERIVATIVES | NETTEKOVEN MATTHIAS HEINRICH | 2009-02-12 | — | — | US | claimed |
| US-7456175-B2 | Piperazinyl-pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-11-25 | — | — | US | claimed |
| EP-1828134-B1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | HOFFMANN LA ROCHE (CH) | 2008-10-29 | — | — | EP | claimed |
| EP-1828134-A1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-09-05 | — | — | EP | claimed |
| US-20060135528-A1 | Piperazinyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | claimed |
| WO-2006063718-A1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | claimed |
| CN-101080392-B | Piperazinyl pyridine derivatives as anti-obesity agents | HOFFMANN LA ROCHE | 2010-05-05 | — | — | CN | disclosed |
| US-7612076-B2 | Piperazinyl-pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090042903-A1 | PIPERAZINYL-PYRIDINE DERIVATIVES | NETTEKOVEN MATTHIAS HEINRICH | 2009-02-12 | — | — | US | disclosed |
| US-7456175-B2 | Piperazinyl-pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1828134-B1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | HOFFMANN LA ROCHE (CH) | 2008-10-29 | — | — | EP | disclosed |
| CN-101080392-A | Piperazinyl pyridine derivatives as anti-obesity agents | HOFFMANN LA ROCHE (CH) | 2007-11-28 | — | — | CN | disclosed |
| EP-1828134-A1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20060135528-A1 | Piperazinyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006063718-A1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135528-A1 | Piperazinyl-pyridine derivatives | HRH4, HRH3, H1-3 | LOXL2 3110/4885LOX 1846/4885HRH3 2/4885 |
| US-20090042903-A1 | PIPERAZINYL-PYRIDINE DERIVATIVES | HRH4, HRH3, H1-3 | LOXL2 3110/4885LOX 1846/4885HRH3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.